Autolus Therapeutics announces publication in Cancer Immunology Research
June 27, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
June 20, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
June 16, 2023 07:00 ET
|
Autolus Therapeutics plc
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months...
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
June 09, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023
June 06, 2023 07:00 ET
|
Autolus Therapeutics plc
LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has posted...
Global and China Passenger Car T-Box Market 2023: T-Box has Started Upgrading to 5G Communication
June 06, 2023 04:38 ET
|
Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global and China Passenger Car T-Box Market Report, 2023" report has been added to ResearchAndMarkets.com's offering.T-Box industry research: the...
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
June 05, 2023 16:30 ET
|
Cellectis Inc.
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate to treat B-NHL, presented at an oral session Encouraging data presented on gene editing process using...
Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO
June 02, 2023 07:00 ET
|
Autolus Therapeutics plc
76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysisPotential best in class...
Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
May 31, 2023 16:50 ET
|
Cellectis Inc.
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub & Collaborations with Leading Experts in Protein Design & Cancer Immunotherapy
May 22, 2023 08:00 ET
|
Outpace Bio
Seattle, WA, May 22, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced the...